A study testing a new treatment called TK-6302 for the first time in people with advanced cancers that have a genetic marker called HLA-A02:01 and a tumour protein called PRAME.

2025-521603-46-00 Protocol TK-6302-01 Human pharmacology (Phase I) - First administration to humans Authorised, recruitment pending

Status Authorised, recruitment pending · 1 EU/EEA countries · 3 sites · Protocol TK-6302-01

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Authorised, recruitment pending
Participants planned 24
Countries 1
Sites 3

Advanced PRAME Positive Solid Tumors

Key facts

Sponsor
T-Knife GmbH
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Decision date (initial)
2026-02-27
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced PRAME Positive Solid Tumors

VersionLevelCodeTermSystem organ class
21.1 LLT 10065143 Malignant solid tumour 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

T-Knife GmbH

Sponsor organisation
T-Knife GmbH
Address
Robert-Roessle-Strasse 10, Buch Buch
City
Berlin
Postcode
13125
Country
Germany

Scientific contact point

Organisation
T-Knife GmbH
Contact name
Michael Loveridge

Public contact point

Organisation
T-Knife GmbH
Contact name
Michael Loveridge

Locations

1 EU/EEA country · 3 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Authorised, recruitment pending 24 3
Rest of world 0

Investigational sites

Germany

3 sites · Authorised, recruitment pending
Technische Universitaet Dresden
Early Clinical Trial Unit (NCT/UCC ECTU), Fetscherstrasse 74, Johannstadt-Nord, Dresden
Charite Universitaetsmedizin Berlin KöR
Med. Klinik m. S. Haematologie, Onkologie und Tumorimmunologie, Augustenburger Platz 1, Wedding, Berlin
University Medical Center Hamburg-Eppendorf
Zentrum fuer Onkologie, II. Medizinische Klinik und Poliklinik, Martinistrasse 52, Eppendorf, Hamburg

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-11-12 Germany Acceptable
2026-02-24
2026-02-27